Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

BACKGROUND: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Kensei, Sawaki, Akira, Doi, Toshihiko, Satoh, Taroh, Yamada, Yasuhide, Omuro, Yasushi, Nishina, Tomohiro, Boku, Narikazu, Chin, Keisho, Hamamoto, Yasuo, Takiuchi, Hiroya, Komatsu, Yoshito, Saji, Shigehira, Koizumi, Wasaburo, Miyata, Yoshinori, Sato, Atsushi, Baba, Eishi, Tamura, Takao, Abe, Takashi, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627028/
https://www.ncbi.nlm.nih.gov/pubmed/22782463
http://dx.doi.org/10.1007/s10120-012-0167-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627028/
https://www.ncbi.nlm.nih.gov/pubmed/22782463
http://dx.doi.org/10.1007/s10120-012-0167-0

Ejemplares similares